NanoSyrinx Secures £10 Million Funding for Biotech Innovation
NanoSyrinx, a pioneering synthetic biology company located in Coventry, UK, recently accomplished a significant milestone by securing approximately £10 million in funding. This funding round, which is a testament to the growing interest and investment in innovative biotechnologies, was spearheaded by prominent investors including BGF, Octopus Ventures, and M Ventures. Notably, the funding also saw the involvement of Eli Lilly and Company as a new corporate investor, as well as existing stakeholders like IQ Capital and Meltwind. The capital raised will be instrumental for NanoSyrinx as it aims to accelerate the growth of its revolutionary platform and to further advance biologic therapeutics that target a range of previously considered 'undruggable' intracellular targets.
Under the leadership of CEO Dr.
Joe Healey, NanoSyrinx is at the forefront of developing a novel synthetic biology platform centered around engineered nanosyringes. These nanosyringes are designed for the targeted intracellular delivery of biological molecules, which is a crucial advancement in the field of therapeutics. The technology leverages naturally occurring nanosyringes that are specifically engineered to selectively deliver payloads such as peptides and proteins directly into the cytosol of targeted cells. This groundbreaking approach holds the potential to enhance the efficacy of treatments by addressing complex diseases at their cellular cores, thereby revolutionizing the way biologic therapeutics are developed and administered.
Furthermore, the company recently announced the pivotal appointment of Dr. Edwin Moses as Chairman of the Board of Directors. Dr. Moses brings a wealth of experience and a proven track record in building and scaling innovative biotech platform companies, with a history of achieving multiple exits and raising over €700 million in equity and debt financing throughout his career. His previous roles include serving as CEO of Ablynx NV, which was acquired by Sanofi for $4.8 billion in 2018, and leading Oxford Asymmetry International plc until its acquisition by Evotec for £316 million. Dr. Moses's extensive experience in navigating the complexities of the biotech industry will prove invaluable as he guides the executive team at NanoSyrinx in maximizing the value derived from the company’s unique nanosyringe platform, through a strategic approach that encompasses both in-house development and commercial partnerships.
They've invested in NanoSyrinx
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  BGF | 21 investment(s) investment(s) | more info | |||
2 |  Octopus Ventures | 35 investment(s) investment(s) | 30 contacts contacts | |||
3 |  M Ventures | 7 investment(s) investment(s) | 19 contacts contacts | |||
4 |  Eli Lilly and Company | 1 investment(s) investment(s) | more info | |||
5 |  IQ Capital | 15 investment(s) investment(s) | 10 contacts contacts |
Click here for a full list of 6,528+ startup investors in the UK